Immunitybio (IBRX) had the highest return between October 27, 2023 and November 20, 2023 by a mid-cap US stock, returning 91.9%.
| ASSET | DATE | % RETURN |
|---|---|---|
Immunitybio (IBRX) | 10/27/2023 - 11/20/2023 | 91.94% |
TransMedics (TMDX) | 10/27/2023 - 11/20/2023 | 81.4% |
Kymera Therapeutics (KYMR) | 10/27/2023 - 11/20/2023 | 80.09% |
TG Therapeutics (TGTX) | 10/27/2023 - 11/20/2023 | 76.58% |
Crispr Therapeutics (CRSP) | 10/27/2023 - 11/20/2023 | 69.84% |
Oscar Health (OSCR) | 10/27/2023 - 11/20/2023 | 68.98% |
Arcellx (ACLX) | 10/27/2023 - 11/20/2023 | 63.57% |
NewAmsterdam Pharma Company NV Ordinary Shares (NAMS) | 10/27/2023 - 11/20/2023 | 52.73% |
Lemonade (LMND) | 10/27/2023 - 11/20/2023 | 52.71% |
Madrigal Pharmaceuticals (MDGL) | 10/27/2023 - 11/20/2023 | 52.32% |
American Superconductor (AMSC) | 10/27/2023 - 11/20/2023 | 49.52% |
HCI (HCI) | 10/27/2023 - 11/20/2023 | 48.14% |
Triumph (TGI) | 10/27/2023 - 11/20/2023 | 44.59% |
Shift4 Payments (FOUR) | 10/27/2023 - 11/20/2023 | 43.95% |
Chefs Warehouse (CHEF) | 10/27/2023 - 11/20/2023 | 43.94% |
Bitdeer Technologies Group Class A Ordinary Shares (BTDR) | 10/27/2023 - 11/20/2023 | 43.81% |
Newmark (NMRK) | 10/27/2023 - 11/20/2023 | 43.59% |
BigBearai (BBAI) | 10/27/2023 - 11/20/2023 | 42.97% |
Akero Therapeutics (AKRO) | 10/27/2023 - 11/20/2023 | 42.84% |
Rhythm Pharmaceuticals (RYTM) | 10/27/2023 - 11/20/2023 | 42.48% |
RLX Technology (RLX) | 10/27/2023 - 11/20/2023 | 42.42% |
StoneCo (STNE) | 10/27/2023 - 11/20/2023 | 42.37% |
Rambus (RMBS) | 10/27/2023 - 11/20/2023 | 41.59% |
SoundHound AI (SOUN) | 10/27/2023 - 11/20/2023 | 41.4% |
Rush Street Interactive (RSI) | 10/27/2023 - 11/20/2023 | 41.39% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
